Aminohippuric acid

Overview

The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

Background

The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

Indication

Used to measure effective renal plasma flow (ERPF) and to determine the functional capacity of the tubular excretory mechanism.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)	2025/04/13	NCT06925750	Phase 2	Recruiting	Merck Sharp & Dohme LLC
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)	2024/10/30	NCT06664801	Phase 2	Active, not recruiting	Merck Sharp & Dohme LLC
Investigations Into Sepsis-associated Acute Kidney Injury	2023/01/23	NCT05694624	N/A	Recruiting	University Hospital of North Norway
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study	2022/09/07	NCT05530356	N/A	ENROLLING_BY_INVITATION	University of Colorado, Denver
Renal Mechanism of SGLT2 Inhibition	2022/08/19	NCT05507892	Phase 2	Recruiting	University of Colorado, Denver
Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)	2022/04/11	NCT05319990	N/A	Recruiting	University of Colorado, Denver
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes	2021/10/04	NCT05065372	Phase 1	Recruiting	Kalie Tommerdahl
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)	2021/08/17	NCT05008276	N/A	Recruiting	Petter Bjornstad
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3	2020/12/02	NCT04649229	Phase 4	Recruiting	Yale University
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)	2020/10/06	NCT04576988	Phase 3	Completed	Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

United Therapeutics Completes Enrollment of Phase 3 Trial for Once-Daily Oral PAH Treatment Ralinepag

11 days ago

United Therapeutics has concluded enrollment of 728 participants in the phase 3 ADVANCE OUTCOMES study evaluating ralinepag, a potential first-in-class once-daily oral prostacyclin agonist for pulmonary arterial hypertension.

Diagonal Therapeutics' DIAG723 Shows Disease-Modifying Potential for Hereditary Hemorrhagic Telangiectasia in Preclinical Studies

16 days ago

Diagonal Therapeutics will present preclinical data at EHA 2025 Congress demonstrating their clustering antibody approach can restore ALK1-mediated cellular signaling and prevent arteriovenous malformations in HHT models.

AI-Powered Research

Premium Access